George Poulogiannis
Team Leader
Signalling & Cancer Metabolism
The Institute Of Cancer Research
United Kingdom
Biography
Dr George Poulogiannis is a Team Leader in the Division of Cancer Biology at the Institute of Cancer Research, London. He received his BSc in Molecular and Cellular Biology from the University of Glasgow and his MSc in Human Molecular Genetics from Imperial College London. He earned his PhD from the University of Cambridge, where he studied the genome abnormalities of colorectal cancer at the laboratory of Prof Andrew Wyllie and Dr Mark Arends. The high demand for analytical skills during his PhD work led him to pursue a second Masters in Computational Biology at the Department of Applied Mathematics and Theoretical Physics at the University of Cambridge, where he was specialized in mathematical modeling of signaling and metabolic networks and analysis of high-throughput datasets. For his postdoctoral research, Dr Poulogiannis joined the laboratory of Prof Lewis Cantley at Harvard Medical School to study the signalling and metabolic networks that are associated with the activation of the PI3K/Akt/mTOR pathway. In 2011, he received the Life Sciences Research Foundation Fellowship for his work entitled "Defining the Genetic and Molecular Circuitry of the Growth-Triggering TOR Pathway" and in 2013, he joined the faculty of ICR to lead the Signalling and Cancer Metabolism team. Dr Poulogiannis is also an academic affiliate of Imperial College and his team is part of the Joint Centre for Systems Oncology and Cancer Innovation. The major focus of his laboratory is to utilize in vitro cell biology approaches, genetically engineered mouse models and high-throughput technologies to study the signalling and metabolic networks that are related to cell growth and oncogenesis.
Research Interest
The research focus of the Poulogiannis lab is to understand the signalling and metabolic networks that are related to cell growth and malignant transformation. In particular, we are interested in deciphering the genetic and molecular pathways that underlie metabolic addiction of cancer cells to known biosynthetic pathways and/or drive cancer cell adaptation to oxygen and nutrient deprivation. In line with these efforts, we aim to explore unique metabolic nodes for novel therapeutic intervention, biomarker selection, and personalized treatment
Publications
-
Day, E., Poulogiannis, G., McCaughan, F., Mulholland, S., Arends, M.J., Ibrahim, A.E. & Dear, P.H. (2013). IRS2 is a candidate driver oncogene on 13q34 in colorectal cancer. International journal of experimental pathology, Vol.94(3), pp. n/a-n/a.
-
Kim, S.G., Hoffman, G.R., Poulogiannis, G., Buel, G.R., Jang, Y.J., Lee, K.W., Kim, B.-., Erikson, R.L., Cantley, L.C., Choo, A.Y., et al. (2013). Metabolic Stress Controls mTORC1 Lysosomal Localization and Dimerization by Regulating the TTT-RUVBL1/2 Complex. Molecular cell, Vol.49(1), pp. 172-185.
-
Luo, F., Poulogiannis, G., Ye, H., Hamoudi, R., Dong, G., Zhang, W., Ibrahim, A.E. & Arends, M.J. (2014). Wild-type K-ras has a tumour suppressor effect on carcinogen-induced murine colorectal adenoma formation. International journal of experimental pathology, Vol.95(1), pp. 8-15.
-
Ip, L.R., Poulogiannis, G., Viciano, F.C., Sasaki, J., Kofuji, S., Spanswick, V.J., Hochhauser, D., Hartley, J.A., Sasaki, T. & Gewinner, C.A., et al. (2015). Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment. Oncotarget, Vol.6(12), pp. 10548-10562.
-
Dimitriadi, M., Derdowski, A., Kalloo, G., Maginnis, M.S., O’Hern, P., Bliska, B., Sorkaç, A., Nguyen, K.C., Cook, S.J., Poulogiannis, G., et al. (2016). Decreased function of survival motor neuron protein impairs endocytic pathways. Proceedings of the national academy of sciences, Vol.113(30), pp. E4377-E4386.
-
Tape, C.J., Ling, S., Dimitriadi, M., McMahon, K.M., Worboys, J.D., Leong, H.S., Norrie, I.C., Miller, C.J., Poulogiannis, G., Lauffenburger, D.A., et al. (2016). Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation. Cell, Vol.165(7), pp. 1818-1818
-
Tape, C.J., Ling, S., Dimitriadi, M., McMahon, K.M., Worboys, J.D., Leong, H.S., Norrie, I.C., Miller, C.J., Poulogiannis, G., Lauffenburger, D.A., et al. (2016). Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation. Cell, Vol.165(4), pp. 910-920.
